About Us
Clinical Trials
Heavy ion radiotherapy in patients with non-resectable osteosarcoma
Title:
Heavy ion radiotherapy in patients with non-resectable osteosarcoma
Indications:
Patients ≥ 6 years with non-resectable or incompletely resected high-grade osteosarcoma with or without metastases
Contact:
Please call one of the following numbers at least 3 weeks before the planned localized therapy:
+49 6221 - 56 5445 Heidelberg Ion-Beam Therapy Center (HIT) or
+49 6221 - 56 6999 Dr. Anne Dittmar, Prof. Dr. Dr. J. Debus (Radiooncology) or
+49 6221 - 56 4002 Dr. Eva Roth, Prof. Dr. Dr. A. Kulozik (Pediatric Oncology)
Enrollment:
July 15, 2010 to July 15, 2015 (scheduled). The enrollment period depends on many factors and may differ from the schedule.
Funding:
Dietmar Hopp Foundation
Overview of study procedures: PDF-file
Accompanying research
Subjects:
- Heavy ion and proton radiotherapy for sarcoma
- Use of histone deacetylase inhibitors combined with radiotherapy for sarcoma
Contact:
Jürgen Debus, MD, PhD / Anne Dittmar, MD
Radiooncology
Heidelberg University Hospital
Im Neuenheimer Feld 400
D - 69120 Heidelberg
Phone: +49 6221 - 56 6999
Email: Anne.Dittmar(at)med.uni-heidelberg.de
Andreas Kulozik, MD, PhD / Eva Roth, MD
Heidelberg University Medical Center for Children and Adolescents
Department of Pediatric Oncology, Hematology, Immunology and Pulmonology
Im Neuenheimer Feld 430
D - 69120 Heidelberg
Phone: +49 6221 - 56 4002
Email: andreas.kulozik(at)med.uni-heidelberg.de eva.roth(at)med.uni-heidelberg.de
Project description
Our research group investigates the use of radiotherapy in treating sarcoma, especially osteosarcoma and rhabdomyosarcoma. We use tumor cell lines, but also xenograft mouse models that are treated with conventional photon radiotherapy and heavy ion / proton radiotherapy. We are especially interested in heavy ion and proton radiotherapy as it produces fewer side effects than conventional photon radiotherapy and is hence a viable treatment alternative for children. In addition, we investigate the use of epigenetically effective agents, histone deacetylase inhibitors and their radiosensitizing effect.
Project funding
Dietmar Hopp Foundation